Pharmaceutical composition comprising NANOG SHRNA, and method of using NANOG SHRNA to treat cancer
The present description relates to an inhibitory RNA molecule, comprising an oligonucleotide that selectively knocks down expression of either Nanog or a Nanog pseudogene, a vector capable of encoding such inhibitory RNA molecule, pharmaceutical compositions comprising said vector, and methods of treating cancer by administration of said pharmaceutical composition.
1. An inhibitory RNA molecule, comprising an oligonucleotide that knocks down expression of either Nanog or NanogP8 wherein the oligonucleotide comprises a sequence of SEQ ID NO:3 (5′-GAGGCAGCAGAGACCGCTGCATGCACTTCCAGCCA-3′) or SEQ ID NO:37 (5′-GAGGCAGCAGAGACCGCTGCATGCAGTTCCAGCCG-3′).
2. The inhibitory RNA molecule of claim 1 , wherein the oligonucleotide knocks down expression of Nanog.
3. The inhibitory RNA molecule of claim 1 , wherein the oligonucleotide knocks down expression of NanogP8.
4. A viral vector, comprising the inhibitory RNA molecule according to claim 1 .
5. The viral vector of claim 4 , wherein the vector is capable of inducing apoptosis of cancer cells.
6. The viral vector of claim 4 , wherein the vector is capable of inhibiting cancer cell proliferation.
7. The viral vector of claim 4 , wherein the vector is capable of inhibiting tumor mass.
8. The viral vector of claim 4 , wherein the viral vector is packaged in a coat protein that specifically binds to colorectal carcinoma (CRC) cells.
9. The viral vector of claim 4 , wherein the viral vector is capable of overexpressing an RNA that inhibits either NanogP8 or Nanog expression.
10. A pharmaceutical composition, comprising the vector according to claim 4 .
11. A pharmaceutical composition, comprising the inhibitory RNA molecule according to claim 1 .
12. A pharmaceutical composition comprising a viral vector, wherein the viral vector is capable of producing the inhibitory RNA molecule according to claim 1 .
13. The pharmaceutical composition of claim 12 , wherein the inhibitory RNA molecule is a double stranded siRNA.
14. An inhibitory RNA molecule, comprising an oligonucleotide that knocks down expression of either Nanog or NanogP8 wherein the oligonucleotide has a sequence of SEQ ID NO:8 (5′-TCTGACAGGAAGTGGCTGGAAGTGCATGCAG-3′) or SEQ ID NO:34 (5′-TCTGACAGGAAGTGGCTGGAACTGCATGCAG-3′).
15. The inhibitory RNA molecule of claim 14 , wherein the oligonucleotide knocks down expression of Nanog.
16. The inhibitory RNA molecule of claim 14 , wherein the oligonucleotide knocks down expression of NanogP8.
17. A viral vector, comprising the inhibitory RNA molecule according to claim 14 .
18. The viral vector of claim 17 , wherein the vector is capable of inducing apoptosis of cancer cells.
19. The viral vector of claim 17 , wherein the vector is capable of inhibiting cancer cell proliferation.
20. The viral vector of claim 17 , wherein the vector is capable of inhibiting tumor mass.
21. The viral vector of claim 17 , wherein the viral vector is capable of overexpressing an RNA that inhibits either NanogP8 or Nanog expression.
22. A pharmaceutical composition, comprising the vector according to claim 17 .
23. A pharmaceutical composition, comprising the inhibitory RNA molecule according to claim 14 .
24. A pharmaceutical composition, comprising a viral vector, wherein the viral vector is capable of producing the inhibitory RNA molecule according to claim 14 .